Crosstalk between the Unfolded Protein Response and NF-κB-Mediated Inflammation in the Progression of Chronic Kidney Disease

Zahraa Mohammed-Ali, Gaile L. Cruz, and Jeffrey G. Dickhout

Department of Medicine, Division of Nephrology, McMaster University and St. Joseph’s Healthcare Hamilton, 50 Charlton Avenue East, Hamilton, ON, Canada L8N 4A6

Correspondence should be addressed to Jeffrey G. Dickhout; jdickhou@stjosham.on.ca

Received 23 July 2014; Accepted 4 September 2014

Academic Editor: Oscar Bottasso

Copyright © 2015 Zahraa Mohammed-Ali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The chronic inflammatory response is emerging as an important therapeutic target in progressive chronic kidney disease. A key transcription factor in the induction of chronic inflammation is NF-κB. Recent studies have demonstrated that sustained activation of the unfolded protein response (UPR) can initiate this NF-κB signaling phenomenon and thereby induce chronic kidney disease progression. A key factor influencing chronic kidney disease progression is proteinuria and this condition has now been demonstrated to induce sustained UPR activation. This review details the crosstalk between the UPR and NF-κB pathways as pertinent to chronic kidney disease. We present potential tools to study this phenomenon as well as potential therapeutics that are emerging to regulate the UPR. These therapeutics may prevent inflammation specifically induced in the kidney due to proteinuria-induced sustained UPR activation.

1. Introduction

Chronic kidney disease (CKD) is a major healthcare concern in the population and its treatment places a large economic burden on healthcare systems. The prevalence of CKD is growing rapidly in North America, thereby increasing cost of hemodialysis and the number of patients requiring organ transplants [1, 2]. CKD can be defined as kidney damage lasting over 3 months caused by structural or functional abnormalities of the kidney, with or without decreased glomerular filtration rate (GFR), that can lead to decreased GFR [3]. Immune cell activation and inflammatory responses are important factors in the development of both acute and chronic kidney diseases [4]. Therefore, immunomodulation therapy may be an important new avenue to help prevent the progression of CKD, reducing patient morbidity and mortality and its associated economic costs.

Endoplasmic reticulum (ER) stress is a cellular pathology that occurs due to an imbalance between protein folding capacity and protein folding demand [5, 6]. The accumulation of misfolded proteins in the ER results from disturbances in ER homeostasis making conditions unfavourable for protein folding, or, mutations in proteins that impair their proper folding [6]. These disturbances in ER homeostasis include hypoxia, glucose depletion, and oxidative stress [7]. ER stress plays an important role in the pathogenesis of chronic diseases associated with the accumulation of misfolded proteins. These include neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases, atherosclerosis, diabetes mellitus and chronic kidney disease [8–10]. ER stress results in the activation of the unfolded protein response (UPR), an evolutionarily conserved cellular response regulated primarily by glucose regulated protein 78-KD (GRP78). The UPR involves the activation of processes such as apoptosis and inflammation that determine the fate of cell survival and tissue scarring [6, 8, 11]. Therefore, ER stress is an important factor in the development of renal diseases and the study of the UPR pathways is likely to reveal molecular targets that influence disease progression.

In this review, we will highlight the current literature on inflammatory and ER stress responses in CKD and then elucidate pathways of ER stress-mediated inflammation that
link these two processes. ER stress-mediated inflammation has been implicated in the pathogenesis and development of several diseases including obesity, type 2 diabetes, inflammatory bowel disease, atherosclerosis, cystic fibrosis, and cancer [11]. Nuclear factor-κB (NF-κB) plays an important role in renal inflammation in human and experimental models of kidney disease [12, 13] and is the main transcription factor in ER stress-mediated inflammation [11, 14, 15]. Therefore, we suggest that ER stress-mediated inflammation could be a key process in CKD development. The study of pathways involved in ER stress-induced inflammation may give rise to highly specific molecular targets that can impact the outcome of CKD progression.

2. Inflammation in Kidney Disease

CKD can lead to end stage renal failure (ESRF), an important comorbidity of cardiovascular disease [16]. Human CKD studies have indicated a relationship between hypertension and renal diseases [17, 18]. Renal T cell and macrophage infiltration has been established in experimental models of hypertension such as in spontaneously hypertensive rats [19, 20], Dahl salt-sensitive rats [21–23], Angiotensin (Ang) II-induced hypertension [24–26], and DOCA-salt hypertension [26–28]. The administration of the immunosuppressive drug, mycophenolate mofetil, appeared to reduce renal inflammation, mesangial cell and macrophage infiltration, oxidative stress, and tubulointerstitial damage in animal models of hypertension [29–31]. Previous reports have shown an improvement in renal function and a reduction in tubular necrosis and immune cell infiltration with T cell deficiency in mouse models of renal ischemic injury [32, 33]. Moreover, in a study by Moon et al., intrarenal CD3+ T cells were increased in proteinuric mice with streptozotocin-induced diabetes [34]. Type 2 diabetic patients also experienced an infiltration of CD4+, CD8+, and CD20+ cells in the renal interstitium where higher levels of CD4+ and CD20+ cells correlated with proteinuria [34]. Therefore, T cells appear to play a role in the development of renal damage in various models of kidney disease. Likewise, macrophage infiltration has been well-established as a prominent characteristic of tubulointerstitial damage that occurs in kidney disease irrespective of the origin [35, 36]. Monocyte chemoattractant protein-1 (MCP-1) is a chemokine known for recruiting macrophages and lymphocytes to sites of tissue injury and infection [37]. Blockade of MCP-1 or its receptor CCR2 has been shown to attenuate macrophage infiltration, renal fibrosis, and tubulointerstitial injury [38–40]. MCP-1 expression has been demonstrated in membranous nephropathy, as an indicator of progression to ESRF [41] and in human crescentic glomerulonephritis where it has been associated with glomerular macrophage infiltration [42]. Also, Urinary excretion of MCP-1 is observed in a majority of adult patients with autosomal dominant polycystic kidney disease [43]. Collectively, these studies suggest an important role for T cells and macrophages in the development and progression of CKD.

Reports have pointed to the significant contribution of the transcription factor, NF-κB, in the pathogenesis of proteinuric renal damage [44–46]. NF-κB is present in an inactive form in all cell types and is released from an inhibitory subunit (IκB) upon stimulation. When released, NF-κB activates the transcription of a large number of target genes: RANTES (regulated upon activation normal T cell expressed and secreted), interleukin (IL)-1, IL-2, IL-6, MCP-1, tumour necrosis factor- (TNF- )α, adhesion molecules, and several other proinflammatory mediators [47]. The inhibition of TNF-α, an NF-κB-inducible gene, has been shown to delay the progression of hypertension and renal damage by reducing proteinuria, urinary MCP-1 excretion, and renal macrophage infiltration in animal models of DOCA salt and Ang II-dependent hypertension [48, 49]. Renal NF-κB expression and/or activation was observed in patients with glomerulonephritis [50, 51], diabetic nephropathy [52], and proteinuric renal disease (minimal change disease and membranous nephropathy) where it correlated with the magnitude of proteinuria [46].

Studies on CKD have established proteinuria as an important modifiable factor in disease progression [53]. Kidney disease patients with a higher mean baseline proteinuria ≥3.0 g/day demonstrated a greater drop in GFR over time [54]. Therefore, the higher the urinary protein excretion values, the faster the decline in GFR and disease progression, making it an important predictor of ESRF independent of the nature of the underlying disease [55]. Protein overload models in vitro using albumin and IgG resulted in an increase in NF-κB activity accompanied by upregulation in NF-κB-inducible genes RANTES and MCP-1 [56]. Cultured rat tubular epithelial cells treated with bovine serum albumin (BSA) showed significant NF-κB activation in a time- and dose-dependent manner [57]. In a rat model of nephritis using uninephrectomy and BSA-overload, nephritic rats experienced an increase in NF-κB activity that correlated with augmentation in urinary protein excretion [57]. This correlation is also observed in rat models of immune complex glomerulonephritis [58], passive Heymann nephritis [59], and renal mass reduction [59]. This finding suggests that NF-κB activation may lead to proinflammatory gene expression and recruitment of inflammatory cells in response to proteinuria. Modulation of NF-κB activity has been performed experimentally [60, 61]. The administration of a recombinant adenovirus vector expressing a truncated form of IκBα in a rat model of tubulointerstitial injury (TI) was able to specifically inhibit NF-κB activation [60]. NF-κB inhibition in this model was able to attenuate proteinuria-induced TI injury as well as TGF-β, VCAM-1, and fibronectin expression in TI lesions [60]. Parthenolide and gliotoxin are able to block NF-κB DNA-binding by stabilizing IκBα. The use of these drugs in experimental models of mesangial proliferative glomerulonephritis leads to lower activation of NF-κB in the glomeruli and tubules of nephritic animals [61]. These agents resulted in decreased proteinuria and glomerular lesions as well as downregulated inflammatory responses and reduced glomerular recruitment of mononuclear cells [61]. Pathways regulated by NF-κB are, therefore, essential in the development of inflammation and proteinuric renal damage in various human and experimental models of kidney disease.
3. ER Stress in Kidney Disease

ER stress leads to the activation of the UPR. The UPR includes the dissociation of GRP78 from three ER transmembrane proteins: PKR (double-stranded RNA-dependent protein kinase) like ER protein kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) [6, 62, 63]. UPR activation causes the release of ATF6 leading to its cleavage in the Golgi by site 1 and site 2 proteases [64, 65]. The cytosolic, DNA-binding fragment of ATF6 travels to the nucleus where it activates the transcription of ER chaperones, enzymes that aid in protein folding and secretion as well as components of ER-associated degradation [62]. PERK is a Ser/Thr protein kinase and is activated through homodimerization and transphosphorylation during the UPR. PERK activation leads to the phosphorylation and inhibition of eIF2α, a component of the translation initiation complex [66, 67]. This pathway reduces the recognition of initiation AUG codon thereby attenuating translation to decrease protein load on the ER. Certain mRNAs with short open reading frames in the 5' untranslated region are preferentially translated in this pathway including ATF4 [66, 67]. ATF4 is a transcription factor that induces the expression of ER stress target genes, notably CHOP, resulting in apoptosis [6, 62]. CHOP is a transcription factor that upregulates expression of proapoptotic factors and decreases antiapoptotic genes such as Bcl2 [6, 62]. IRE1α activation results in X-box binding protein-1 (XBP1) mRNA splicing. This step causes a change in the reading frame allowing the translation of a transcription factor that induces expression of genes with an ER stress response element including ER chaperones such as GRP78 [62, 68–70]. The IRE1α arm of the UPR may also stimulate proapoptotic pathways via its activation of Caspase 12 (rodents)/Caspase 4 (humans) and c-Jun N-terminal kinase (JNK) phosphorylation [62, 68–70].

Kidney biopsies from patients at different stages of glomerulonephritis showed upregulation of GRP78 and CHOP highlighting the significance of ER stress responses in renal disease progression [71]. The upregulation of ER stress markers has also been shown in nephrotic syndrome patients [72]. ER stress pathways may be targeted pharmacologically to attempt to modify the outcome of renal disease [62]. The use of 4-phenylbutyric acid (4-PBA), a low molecular weight chemical chaperone, prevented ER stress in a rat model of streptozotocin-induced diabetic nephropathy and also significantly reduced urinary protein excretion [73]. Treatment with 4-PBA in this model also reduced basement membrane thickening, mesangial cell proliferation, and mesangial matrix accumulation in rats with diabetic nephropathy [74]. Similarly, 4-PBA was able to cause a significant decrease in fibrosis as shown by marked reduction in collagen type I, fibronectin, and α-SMA in rats undergoing the unilateral ureteral obstruction model [74].

In a model of acute kidney injury, 4-PBA treatment prevented damage to the outer medullary stripe of the kidney and reduced ER stress upregulation and CHOP-induced apoptosis [75]. Further, the deletion of the GRP78 ER retention sequence, KDEL, has been shown to exacerbate renal injury by increased urinary protein excretion and tubular damage in an in vivo model of albumin overload [76]. Therefore, the manipulation of the UPR has a significant impact on CKD progression.

4. Interrelationship between Inflammatory Pathways and ER Stress in Kidney Disease

All three arms of the UPR, IRE1α, PERK, and ATF6 result in transcriptional activation of proinflammatory genes by primarily activating NF-κB [14, 15, 77]. In mammals, the NF-κB family consists of five members: p65/RelA, cRel, RelB, p100/p52, and p105/p50 [12]. These proteins can homodimerize and form heterodimers with each other and share a highly conserved domain, Rel homology region (RHR) [12, 78, 79]. NF-κB dimers are bound to inhibitory IκB proteins in the cytoplasm and are inactive since IκB interferes with the function of the nuclear localization sequence present on the RHR domain [80]. Phosphorylation and subsequent degradation of IκB is required for NF-κB translocation to the nucleus [78].

Figure 1 shows an overview of the pathways involved in ER stress-mediated activation of inflammatory gene transcription. During prolonged ER stress, the dissociation of GRP78 results in autophosphorylation of IRE1α causing a conformational change in its cytosolic domain. The cytosolic domain of activated IRE1α then binds to adaptor protein TNFα receptor-associated factor 2 (TRAF2) [81]. The IRE1α-TRAF2 complex recruits IκB kinase (IKK), phosphorylating IκB resulting in its degradation and NF-κB activation [82, 83]. IRE1α-TRAF2 complex can also recruit protein kinase JNK leading to phosphorylation of transcription factor API, linking ER stress to other proinflammatory pathways [84]. UPR activation of PERK results in translation attenuation via phosphorylation of eIF2α, a component of the translation initiation complex. This process causes decreased translation of IκB, freeing more NF-κB to translocate to the nucleus [85, 86]. ATF6 leaves the ER upon activation and undergoes cleavage by site 1 and site 2 proteases in the Golgi complex. These activated ATF6 fragments form homodimers and induce transcription of acute-phase response genes [14, 64, 65]. Although the ATF6 pathway can also result in NF-κB activation via phosphorylation of Akt [87], the PERK and IRE1α arms of the UPR have been demonstrated as crucial for ER stress-induced NF-κB activation. In a study by Kaneko et al. [82], human embryonic kidney (HEK) 293T cells treated with thapsigargin (TG) showed phosphorylation and degradation of IκB and upregulation of NF-κB. This effect was suppressed with transfection of a dominant-negative mutant of IRE1α or a dominant-negative mutant of TRAF2 [82]. ER stress-induced activation of NF-κB using thapsigargin and tunicamycin was impared with IRE1α knockdown and IRE1α deficiency in mouse embryonic fibroblasts (MEFs) [83]. Reconstitution of IRE1α deficient MEFs with IRE1α resulted in the recovery of ER stress-induced NF-κB activation [83]. Similarly, studies have shown eIF2α phosphorylation results in NF-κB activation through translation attenuation as it occurs independently of IκB phosphorylation or degradation [85, 86]. Moreover, PERK deficiency and eIF2α mutant MEFs inhibited NF-κB activation in response to treatment with ER.
stress inducing agents indicating that PERK-induced eIF2α phosphorylation is essential in NF-κB activation [85].

5. Investigating ER Stress-Induced Inflammation in the Kidney

Since ER stress pathways and inflammatory responses have been demonstrated in human CKD as well as in animal models of the disease, the use of pharmacological tools in vitro and in vivo may help elucidate molecular targets essential to disease progression. Table 1 summarizes drugs that could be used to manipulate the UPR.

Salubrinal (Sal) is a small molecule identified through high-throughput screening for its ability to enable cells to withstand ER stress. This drug acts as a phosphatase inhibitor specific in preventing the activation of eIF2α, a key component of the PERK pathway [88]. In vivo, Sal has been shown to protect against cyclosporine A-induced nephrotoxicity [89], which has been associated with ER stress [90]. GSK2606414 is a potent and selective PERK inhibitor shown to inhibit PERK activation in response to ER stress in A549 cells, a human lung adenocarcinoma cell line, and inhibits the growth of human tumor xenografts in mice [91]. Since it penetrates the blood-brain barrier, GSK2606414 administration has been shown to impart neuroprotective effects and prevent clinical disease in prion-infected mice [92]. Therefore, Sal and GSK2606414 provide pharmacological interventions that could be used to study the effect of the PERK pathway on ER stress-induced inflammation.

STF 083010 is a novel molecule, first identified though high-throughput screening. This reagent was able to inhibit IRE1α endonuclease activity during ER stress both in vitro and in vivo. Pretreatment of RPMI 8226 human multiple myeloma cells with STF 083010 blocked XBP1 splicing activated by both tunicamycin- and thapsigargin-induced ER stress. Additionally, treatment of XBPI-luciferase reporter
mice with STF 083010 reduced XBP1 splicing in an in vivo model of ER stress induced by bortezomib [93]. Irestatin is another molecule that is able to inhibit IRE1α endonuclease activity and has been reported to disrupt the growth of malignant myeloma cells [94]. Therefore, STF 083010 as well as Irestatin could be used as pharmacological tools to study the effect of inhibiting the IRE1α pathway on ER stress-induced inflammation.

4-(2-Aminoethyl) benzenesulfonyl fluoride (AEBSF) has been shown to prevent ER stress-induced cleavage of ATF6α and ATF6β, resulting in inhibition of transcriptional induction of ATF6-target genes [95]. This compound has been used as a serine protease inhibitor in both in vitro [96, 97] and in vivo studies [98, 99]. Therefore, AEBSF could be used as a pharmacological tool to study the effect of inhibiting the ATF6 pathway on ER stress-induced inflammation.

4-PBA is a chemical chaperone that has been shown to stabilize protein conformation and improve protein folding in the ER by inhibiting ER stress. This drug has been used clinically for the treatment of urea cycle disorders in children, sickle cell disease, thalassemia and cystic fibrosis [100]. In particular, in vitro studies have shown that 4-PBA administration results in a reduction in GRP78 levels in response to ER stress [101, 102]. In a mouse model of brain ischemia, pretreatment or posttreatment with 4-PBA at therapeutic doses was able to attenuate disease progression possibly as a result of a decrease in protein load retained by the ER [103]. Tauroursodeoxycholate (TUDCA), a derivative of an endogenous bile acid, is another chaperone that has been shown to resolve ER stress in liver and adipose tissue thereby normalizing hyperglycemia and restoring systemic insulin sensitivity in obese and diabetic mice [104]. TUDCA has also been shown to inhibit the expression of ER stress markers in intestinal epithelial cells [105] and attenuate intestinal inflammation in a rodent model of inflammatory bowel disease [106]. Therefore, both 4-PBA and TUDCA could be used to manipulate ER stress responses.

ER stress-inducing agents tunicamycin (TM), thapsigargin (TG), and indoxyl sulfate (IS) could be used to evaluate the effects of ER stress induction in vitro and in vivo. TM is a nucleoside antibiotic, which inhibits N-linked protein glycosylation, and is used to model acute kidney injury in vivo [75]. TG is a plant-derived sesquiterpene lactone and induces ER stress by inhibiting the sarcoplasmic/ endoplasmic reticulum calcium ATPase (SERCA) pump and altering Ca²⁺ homeostasis [107]. Both TM and TG result in upregulation of ER stress markers GRP78, GRP94, CHOP, and phosphorylated eIF2α in human proximal tubule cells [75, 108, 109]. IS is a uremic toxin that has been reported to accumulate in the serum of CKD patients and contribute to disease progression [110, 111]. IS interacts with organic anion transporter types 1 and 3 and is therefore able to incorporate into the basolateral membrane of renal proximal tubule cells [112]. IS was shown to induce ER stress via oxidative stress in human proximal tubule cells and inhibits cell proliferation through the upregulation of CHOP and ATF4 in these cells [113].

Human kidney proximal tubule cells (HK2 cell line) [114] could be used to generate a reporter cell line for XBP1 splicing. A previously published tool for monitoring XBP1 splicing involves an ER stress-activated indicator (ERAI) [115]. The ERAI consists of a F-XBP1DBD-venus plasmid, a variant of green fluorescent protein, fused as a reporter downstream.

---

### Table 1: Pharmacological manipulation of the UPR

| UPR gene        | Pharmacological manipulation | Description                                                                                           |
|-----------------|------------------------------|--------------------------------------------------------------------------------------------------------|
| PERK            | Salubrinal                   | Phosphatase inhibitor prevents dephosphorylation of eIF2α                                                |
|                 | GSK2606414                   | Potent and selective PERK inhibitor                                                                      |
| IRE1α           | STF083010                    | Specifically inhibits IRE1α endonuclease activity during ER stress without affecting its kinase activity |
|                 | Irestatin                    | Specific inhibitor of IRE1α                                                                               |
| ATF6            | 4-(2-Aminoethyl) benzenesulfonyl fluoride (AEBSF) | Serine protease inhibitor inhibits site 1 and site 2 proteases preventing ATF6 cleavage and inhibits transcription of ATF6 target genes |
| Small chemical protein folding chaperones | 4-Phenybutyrate (4-PBA) | 4-PBA and TUDCA aid in protein folding reducing misfolded protein accumulation in the ER |
|                 | Tauroursodeoxycholic acid (TUDCA) | Inhibitor of N-linked protein glycosylation hinders a process required for proper protein folding |
| UPR activating agents | Tunicamycin | Inhibitor of sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) pump causes ER stress |
|                 | Thapsigargin                 | Uremic toxin that causes ER stress via oxidative stress                                                  |
|                 | Indoxyl sulfate              |                                                                                                         |
Figure 2: Detection of XBP1 splicing in human proximal tubule-2 cells using XBP1sVenus reporter. (a) XBP1sVenus was placed in a hygromycin B selectable cassette and transfected into HK-2 cells. Cells were then selected for stable incorporation of XBP1sVenus with 0.5 mg/mL hygromycin B. Clones were screened with 1 μg/mL tunicamycin (Tm) for 6 or 18 hours. Clones 3, 12, and 16 were found to give robust responses when probed with the flag-tag antibody and produced green fluorescence. (b) Clone 12 from the stably transfected XBP1s HK-2 reported cell line was grown up and untreated (Un) or treated with 1 μg/mL tunicamycin (Tm). The expression of the flag-tag shows IRE1 activation in the reporter cell line.

A number of pharmacological and genetic tools are available to study ER stress-induced inflammation in the kidney both in vivo and in vitro. Manipulation of ER stress pathways will provide insight about the influence of the UPR on the inflammatory response and might reveal useful and more specific targets in key processes during CKD development.

6. Conclusion

ER stress-mediated inflammation appears to be important in the progression of CKD. Further, specific pathways within the UPR response result in ER stress-induced inflammation. Thus, the targeted pharmacological manipulation of the UPR holds promise to selectively inhibit the inflammatory consequences of UPR activation without disrupting proteostasis.

Conflict of Interests

The authors declare that there is no conflict of interests regarding publication of this paper.

Acknowledgments

This work was supported by research grants to Jeffrey G. Dickhout from the Canadian Institutes of Health Research (OSO-115895 and MOP-133484). Financial support from St. Joseph’s Healthcare Hamilton is also acknowledged. Jeffrey G. Dickhout also acknowledges salary support from St. Joseph’s Healthcare Hamilton and holds a McMaster University Department of Medicine Internal Career Research Award. Support from the Division of Nephrology at the Department of Medicine in McMaster University is also acknowledged. Dr. Dickhout also holds a Kidney Foundation of Canada Krescent New Investigator Award.

References

[1] P. Stenvinkel, “Chronic kidney disease: A public health priority and harbinger of premature cardiovascular disease,” Journal of Internal Medicine, vol. 268, no. 5, pp. 456–467, 2010.
[2] P. Arora, P. Vasa, D. Brenner et al., “Prevalence estimates of chronic kidney disease in Canada: results of a nationally
representative survey,” *CMAJ*, vol. 185, no. 9, pp. E417–E423, 2013.

[3] A. S. Levey, K.-U. Eckardt, Y. Tsukamoto et al., “Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO),” *Kidney International*, vol. 67, no. 6, pp. 2089–2100, 2005.

[4] J. D. Imig and M. J. Ryan, “Immune and inflammatory role in renal disease,” *Comprehensive Physiology*, vol. 3, no. 2, pp. 957–976, 2013.

[5] G. Remuzzi and T. Bertani, “Pathophysiology of progressive nephropathies,” *The New England Journal of Medicine*, vol. 339, no. 20, pp. 1448–1456, 1998.

[6] J. G. Dickhout and J. C. Krepsinsky, “Endoplasmic reticulum stress and renal disease,” *Antioxidants and Redox Signaling*, vol. 11, no. 9, pp. 2341–2352, 2009.

[7] R. Inagi, “Endoplasmic reticulum stress in the kidney as a novel mediator of kidney injury,” *Nephron: Experimental Nephrology*, vol. 112, no. 1, pp. e1–e9, 2009.

[8] C. Xu, B. Bailly-Maitre, and J. C. Reed, “Endoplasmic reticulum stress: cell life and death decisions,” *Journal of Clinical Investigation*, vol. 115, no. 10, pp. 2656–2664, 2005.

[9] H. Yoshida, “ER stress and diseases,” *The FEBs Journal*, vol. 274, no. 3, pp. 630–658, 2007.

[10] K. Zhang and R. J. Kaufman, “The unfolded protein response: a stress signaling pathway critical for health and disease,” *Neurology*, vol. 66, supplement 1, no. 2, pp. S102–S109, 2006.

[11] A. D. Garg, A. Kaczmarek, O. Krysko, P. Vandenabeele, D. V. Krysko, and P. Agostinis, “ER stress-induced inflammation: does it aid or impede disease progression?” *Trends in Molecular Medicine*, vol. 18, no. 10, pp. 589–598, 2012.

[12] A. B. Sanz, M. D. Sanchez-Nino, A. M. Ramos et al., “NF-xB in renal inflammation,” *Journal of the American Society of Nephrology*, vol. 21, no. 8, pp. 1254–1262, 2010.

[13] S. Klahr and J. J. Morrissey, “The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease,” *Kidney International, Supplement*, vol. 57, no. 75, pp. S7–S17, 2000.

[14] K. Zhang and R. J. Kaufman, “From endoplasmic-reticulum stress to the inflammatory response,” *Nature*, vol. 454, no. 7203, pp. 455–462, 2008.

[15] S. Z. Hasnain, R. Lourie, I. Das, A. C.-H. Chen, and M. A. McGuckin, “The interplay between endoplasmic reticulum stress and inflammation,” *Immunology and Cell Biology*, vol. 90, no. 3, pp. 260–270, 2012.

[16] P. P. Liu, “Cardiorenal syndrome in heart failure: a cardiologist’s perspective,” *Canadian Journal of Cardiology*, vol. 24, pp. 25B–29B, 2008.

[17] M. J. Klag, P. K. Whelton, B. L. Randall et al., “Blood pressure and end-stage renal disease in men,” *The New England Journal of Medicine*, vol. 334, no. 1, pp. 13–18, 1996.

[18] P. K. Whelton, T. V. Perneger, J. He, and M. J. Klag, “The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence,” *Journal of Human Hypertension*, vol. 10, no. 10, pp. 683–689, 1996.

[19] B. Rodriguez-Iturbe, Y. Quiroz, M. Nava et al., “Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats,” *The American Journal of Physiology—Renal Physiology*, vol. 282, no. 2, pp. F191–F201, 2002.

[20] D. Ba, N. Takeichi, T. Kodama, and H. Kobayashi, “Restoration of T cell depression and suppression of blood pressure in spontaneously hypertensive rats (SHR) by thymus grafts or thymus extracts,” *The Journal of Immunology*, vol. 128, no. 3, pp. 1211–1216, 1982.

[21] N. Tian, J.-W. Gu, S. Jordan, R. A. Rose, M. D. Hughson, and R. D. Manning Jr., “Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension,” *The American Journal of Physiology: Heart and Circulatory Physiology*, vol. 292, no. 2, pp. H1018–H1025, 2007.

[22] D. L. Mattson, L. James, E. A. Berdan, and C. J. Meister, “Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat,” *Hypertension*, vol. 48, no. 1, pp. 149–156, 2006.

[23] C. de Miguel, S. Das, H. Lund, and D. L. Mattson, “T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats,” *American Journal of Physiology—Regulatory Integrative and Comparative Physiology*, vol. 298, no. 4, pp. R1136–R1142, 2010.

[24] T.-D. Liao, X.-P. Yang, Y.-H. Liu et al., “Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension,” *Hypertension*, vol. 52, no. 2, pp. 256–263, 2008.

[25] R. J. Johnson, C. E. Alpers, A. Yoshimura et al., “Renal injury from angiotensin II-mediated hypertension,” *Hypertension*, vol. 19, no. 5, pp. 464–474, 1992.

[26] T. J. Guzik, N. E. Hoch, K. A. Brown et al., “Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction,” *Journal of Experimental Medicine*, vol. 204, no. 10, pp. 2449–2460, 2007.

[27] R. A. Beswick, H. Zhang, D. Marable, J. D. Catravas, W. D. Hill, and R. Clinton Webb, “Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response,” *Hypertension*, vol. 37, no. 2, part 2, pp. 781–786, 2001.

[28] E. R. Blasi, R. Rocha, A. E. Rudolph, E. A. G. Blomme, M. L. Polly, and E. G. McMahon, “Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats,” *Kidney International*, vol. 63, no. 5, pp. 1791–1800, 2003.

[29] B. Rodriguez-Iturbe, H. Pons, Y. Quiroz et al., “Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure,” *Kidney International*, vol. 59, no. 6, pp. 2222–2232, 2001.

[30] Y. Quiroz, H. Pons, K. L. Gordon et al., “Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition,” *American Journal of Physiology—Renal Physiology*, vol. 281, no. 1, pp. F38–F47, 2001.

[31] V. Alvarez, Y. Quiroz, M. Nava, H. Pons, and B. Rodriguez-Iturbe, “Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells,” *The American Journal of Physiology—Renal Physiology*, vol. 283, no. 5, pp. F1132–F1141, 2002.

[32] H. Rabb, F. Daniels, M. O’Donnell et al., “Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice,” *American Journal of Physiology—Renal Physiology*, vol. 279, no. 3, pp. F525–F531, 2000.

[33] M. J. Burne, F. Daniels, A. El-Ghandour et al., “Identification of the cd4+ T cell as a major pathogenic factor in ischemic acute renal failure,” *Journal of Clinical Investigation*, vol. 108, no. 9, pp. 1283–1290, 2001.

[34] J.-Y. Moon, K.-H. Jeong, T.-W. Lee, C.-G. Ihm, S. J. Lim, and H. Rabinowitz, “Pathophysiological role of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats (SHR) by thymus grafts or thymus extracts,” *The Journal of Immunology*, vol. 128, no. 3, pp. 1211–1216, 1982.
C. Zozia, R. Donadelli, S. Colleoni et al., “Proteinoverloadstimu-
lation of diet in renal disease study,” Kidney International, vol. 68, no. 2, pp. 437–455, 2005.

S. L. Deshmek, S. Kremlev, S. Amini, and B. E. Sawaya, “Monocyte chemoattractant protein-1 (MCP-1): an overview,” Journal of Interferon and Cytokine Research, vol. 29, no. 6, pp. 313–325, 2009.

H. Shimizu, S. Maruyama, Y. Yuzawa et al., “Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria,” Journal of the American Society of Nephrology, vol. 14, no. 6, pp. 1496–1505, 2003.

T. Wada, K. Furuichi, N. Sakai et al., “Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis,” Journal of the American Society of Nephrology, vol. 15, no. 4, pp. 940–948, 2004.

K. Kitagawa, T. Wada, K. Furuichi et al., “Blockade of CCR2 ameliorates progressive fibrosis in kidney,” The American Journal of Pathology, vol. 165, no. 1, pp. 237–246, 2004.

K. Yoshimoto, T. Wada, K. Furuichi, N. Sakai, K. Ikawa, and H. Yokoyama, “CD68 and MCP-1/CCR2 expression of initial biopsies reflect the outcomes of membranous nephropathy,” Nephron Clinical Practice, vol. 98, no. 1, pp. c25–c34, 2004.

S. Segerer, R. Cui, K. L. Hudkins et al., “Expression of the chemokine monocyte chemoattractant protein-1 and its receptor chemokine receptor 2 in human crescentic glomeru-

lonephritis,” Journal of the American Society of Nephrology, vol. 11, no. 12, pp. 2231–2242, 2000.

D. Zheng, W. Wolfe, B. D. Cowley Jr., D. P. Wallace, T. Yamaguchi, and J. J. Grantham, “Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2588–2595, 2003.

C. Zozia, R. Donadelli, S. Colleoni et al., “Protein overload stimu-
lates RANTES production by proximal tubular cells depending on NF-κB activation,” Kidney International, vol. 53, no. 6, pp. 1608–1615, 1998.

C. Guijarro and J. Egidio, “Transcription factor-κB (NF-κB) and renal disease,” Kidney International, vol. 59, no. 2, pp. 415–424, 2001.

S. A. Mezzano, M. Barria, M. A. Droguett et al., “Tubular NF-κB and AP-1 activation in human proteinuric renal disease,” Kidney International, vol. 60, no. 4, pp. 1366–1377, 2001.

M. Praga and E. Morales, “Renal damage associated with proteinuria,” Kidney International, Supplement, vol. 62, no. 82, pp. S42–S46, 2002.

A. A. Elmarakby, J. E. Quigley, D. M. Pollock, and J. D. Imig, “Tumor necrosis factor α blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension,” Hypertension, vol. 47, no. 3, pp. 557–562, 2006.

A. A. Elmarakby, J. E. Quigley, J. D. Imig, J. S. Pollock, and D. M. Pollock, “TNF-α inhibition reduces renal injury in DOCA-salt hypertensive rats,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 294, no. 1, pp. R76–R83, 2008.

N. Sakai, T. Wada, K. Furuichi et al., “p38 MAPK phosphorylation and NF-κB activation in human crescentic glomeru-
lonephritis,” Nephrology Dialysis Transplantation, vol. 17, no. 6, pp. 998–1004, 2002.

L. Zheng, R. Sinniah, and S. I.-H. Hsu, “In situ glomerular expression of activated NF-κB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy,” Virchows Archiv, vol. 448, no. 2, pp. 172–183, 2006.

S. Mezzano, C. Aros, A. Droguett et al., “NF-κB activation and overexpression of regulated genes in human diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 19, no. 10, pp. 2505–2512, 2004.

A. M. El Nahas and A. K. Bello, “Chronic kidney disease: The global challenge,” The Lancet, vol. 365, no. 9456, pp. 331–340, 2005.

J. C. Peterson, S. Adler, J. M. Burkart et al., “Blood pressure control, proteinuria, and the progression of renal disease: the modification of diet in renal disease study,” Annals of Internal Medicine, vol. 123, no. 10, pp. 754–762, 1995.

P. Ruggenenti, A. Perna, L. Mosconi, R. Pisoni, and G. Remuzzi, “Urinary protein excretion rate is the best independent predi-
tor of ESRF in non-diabetic proteinuric chronic nephropathies,” Kidney International, vol. 53, no. 5, pp. 1209–1216, 1998.

M. Morigi, D. Macconi, C. Zozia et al., “Protein overload-induced NF-κB activation in proximal tubular cells requires H2O2 through a PKC-dependent pathway,” Journal of the American Society of Nephrology, vol. 13, no. 5, pp. 1179–1189, 2002.

D. Gómez-Garre, R. Largo, N. Tejera, J. Fortes, F. Manzarbeitia, and J. Egidio, “Activation of NF-κB in tubular epithelial cells of rats with intense proteinuria role of angiotensin II and endothelin-1,” Hypertension, vol. 37, no. 4, pp. 1171–1178, 2001.

M. Ruiz-Ortega, C. Bustos, M. A. Hernández-Presa, O. Lorenzo, J. J. Plaza, and J. Egidio, “Angiotensin II participates in mononuclear cell recruitment in experimental immune com-
plex nephritis through nuclear factor-κB activation and mono-
cyte chemoattractant protein-1 synthesis,” Journal of Immunology, vol. 161, no. 1, pp. 430–439, 1998.

R. Donadelli, M. Abbate, C. Zanchi et al., “Protein traffic acti-
vates NF-κB gene signaling and promotes MCP-1-dependent interstitial inflammation,” The American Journal of Kidney Diseases, vol. 36, no. 6, pp. 1226–1241, 2000.

O. Takase, J. Hirahashi, A. Takayanagi et al., “Gene transfer of truncated IκBκ prevents tubulointerstitial injury,” Kidney International, vol. 65, no. 2, pp. 501–513, 2003.

O. López-Francos, Y. Suzuki, G. Sanjuan et al., “Nuclear factor-
κB inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis,” The American Journal of Pathology, vol. 161, no. 4, pp. 1497–1505, 2002.

R. Inagi, “Endoplasmic reticulum stress as a progression factor for kidney injury,” Current Opinion in Pharmacology, vol. 10, no. 2, pp. 156–165, 2010.

A. V. Cybulsky, “Endoplasmic reticulum stressin proteinuric kidney disease,” Kidney International, vol. 77, no. 3, pp. 187–193, 2010.

J. Ye, R. B. Rawson, R. Komuro et al., “ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBP1,” Molecular Cell, vol. 6, no. 6, pp. 1355–1364, 2000.

K. Zhang, X. Shen, J. Wu et al., “Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response,” Cell, vol. 124, no. 3, pp. 587–599, 2006.

R. J. Kaufman, “Regulation of mRNA translation by protein folding in the endoplasmic reticulum,” Trends in Biochemical Sciences, vol. 29, no. 3, pp. 152–158, 2004.
[97] Š. Lhoták, S. Sood, E. Brimble et al., "ER stress contributes to renal proximal tubule injury by increasing SREBP-2-mediated lipid accumulation and apoptotic cell death," American Journal of Physiology—Renal Physiology, vol. 303, no. 2, pp. F266–F278, 2012.

[98] R. Buitrago-Rey, J. Olarte, and J. E. Gomez-Marin, "Evaluation of two inhibitors of invasion: LY311727 [3-(3-acetamide-1-benzyl-2-ethyl-indolyl-5-oxy)propane phosphonic acid] and AEBSF [4-(2-aminoethyl)-benzenesulphonyl fluoride] in acute murine toxoplasmosis," Journal of Antimicrobial Chemistry, vol. 49, no. 5, pp. 871–874, 2002.

[99] K. Zen, Y.-L. Guo, L.-M. Li, Z. Bian, C.-Y. Zhang, and Y. Liu, "Cleavage of the CD11b extracellular domain by the leukocyte serprocidins is critical for neutrophil detachment during chemotaxis," Blood, vol. 117, no. 18, pp. 4885–4894, 2011.

[100] D. H. Perlmutter, "Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking," Pediatric Research, vol. 52, no. 6, pp. 832–836, 2002.

[101] S. Basseri, Š. Lhoták, A. M. Sharma, and R. C. Austin, "The chemical chaperon 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response," Journal of Lipid Research, vol. 50, no. 12, pp. 2486–2501, 2009.

[102] X. Liu, S. C. Doné, K. Yan, P. Kilpeläinen, T. Pikkarainen, and K. Tryggvason, "Defective trafficking of nephrin missense mutants rescued by a chemical chaperone," Journal of the American Society of Nephrology, vol. 15, no. 7, pp. 1731–1738, 2004.

[103] X. Qi, T. Hosoi, Y. Okuma, M. Kaneko, and Y. Nomura, "Sodium 4-phenylbutyrate protects against cerebral ischemic injury," Molecular Pharmacology, vol. 66, no. 4, pp. 899–908, 2004.

[104] U. Özcan, E. Yilmaz, L. Özcan et al., "Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes," Science, vol. 313, no. 5790, pp. 1137–1140, 2004.

[105] E. Berger and D. Haller, "Structure-function analysis of the tertiary bile acid TUDCA for the resolution of endoplasmic reticulum stress in intestinal epithelial cells," Biochemical and Biophysical Research Communications, vol. 409, no. 4, pp. 610–615, 2011.

[106] A. Uchida, T. Yamada, T. Hayakawa, and M. Hoshino, "Taurochenoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation," American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 272, no. 5, part 1, pp. G1249–G1257, 1997.

[107] J. Lytton, M. Westlin, and M. R. Hanley, "Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps," The Journal of Biological Chemistry, vol. 266, no. 26, pp. 17067–17071, 1991.

[108] J. G. Dickhout, R. E. Carlisle, D. E. Jerome et al., "Integrated stress response modulates cellular redox state via induction of cystathionine γ-lyase: cross-talk between integrated stress response and thiol metabolism," The Journal of Biological Chemistry, vol. 287, no. 10, pp. 7603–7614, 2012.

[109] R. E. Carlisle, A. Heffernan, E. Brimble et al., "TDAG51 mediates epithelial-to-mesenchymal transition in human proximal tubular epithelium," American Journal of Physiology: Renal Physiology, vol. 303, no. 3, pp. F467–F481, 2012.

[110] F. C. Barreto, D. V. Barreto, S. Liabeuf et al., "Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients," Clinical Journal of the American Society of Nephrology, vol. 4, no. 10, pp. 1551–1558, 2009.